What Are the Special Properties of MRSA Prodrug TXA709?

Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, co-founder of TAXIS Pharmaceuticals, explains how the initial drug discovery process for MRSA drug TX709 evolved. The vision was to develop a drug that could be orally bioavailable, but still have a sustained effect. Dr. LaVoie explains how TXA709 has "necessary properties" that allow for it to be formulated for infusion. TXA709 has proved efficacious by the intravenous and oral routes in animal model studies, which offers significant clinical advantages.